Elabela peptides (ELA) are a body-own peptide hormone class that bind to the APJ receptor, a rhodopsin-like G-protein coupled receptor (GPCR). APJ receptor activation triggers physiological functions such as cardiovascular development and output, water metabolism and cell signaling. ELA peptides originate from a 54-amino acid prepropeptide that is processed in shorter isoforms such as ELA-32, ELA-21, and ELA-11. The C-terminal 10 amino acids are the minimum consensus structures to activate the receptor. The shortest ELA-10 isoforms display a biased response towards the activation of downstream pathways which is beneficial in prolonging physiological effects of this peptide and suppressing unwanted pathways. ELA-isoforms possess a short plasma half-life estimated to be &lt;1.4min. PEGylation can successfully extend the plasma half-life up to three orders of magnitude. The goal of this project is the solid-phase assisted synthesis and purification of ELA-10 and ELA-14 analogues with an N-terminal PEG-6 chain to study if extension increases metabolic stability and (biased) physiological activity.

PEGylated Elabela peptides as potential therapeutics for cardiovascular disease

ACS Spring 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.